These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
370 related articles for article (PubMed ID: 25256262)
1. The next generation of HPV vaccines: nonavalent vaccine V503 on the horizon. Chatterjee A Expert Rev Vaccines; 2014 Nov; 13(11):1279-90. PubMed ID: 25256262 [TBL] [Abstract][Full Text] [Related]
3. Potential impact of a nonavalent HPV vaccine on the occurrence of HPV-related diseases in France. Riethmuller D; Jacquard AC; Lacau St Guily J; Aubin F; Carcopino X; Pradat P; Dahlab A; Prétet JL BMC Public Health; 2015 May; 15():453. PubMed ID: 25934423 [TBL] [Abstract][Full Text] [Related]
4. Introducing human papillomavirus vaccines - questions remain. Paavonen J; Lehtinen M Ann Med; 2008; 40(3):162-6. PubMed ID: 18382882 [TBL] [Abstract][Full Text] [Related]
5. 9-Valent HPV vaccine for cancers, pre-cancers and genital warts related to HPV. Pitisuttithum P; Velicer C; Luxembourg A Expert Rev Vaccines; 2015; 14(11):1405-19. PubMed ID: 26366475 [TBL] [Abstract][Full Text] [Related]
6. Potential cost-effectiveness of the nonavalent human papillomavirus (HPV) vaccine. Drolet M; Laprise JF; Boily MC; Franco EL; Brisson M Int J Cancer; 2014 May; 134(9):2264-8. PubMed ID: 24174175 [TBL] [Abstract][Full Text] [Related]
7. Quadrivalent human papillomavirus (HPV) vaccine: a review of safety, efficacy, and pharmacoeconomics. Pomfret TC; Gagnon JM; Gilchrist AT J Clin Pharm Ther; 2011 Feb; 36(1):1-9. PubMed ID: 21198715 [TBL] [Abstract][Full Text] [Related]
8. From the monovalent to the nine-valent HPV vaccine. Pils S; Joura EA Clin Microbiol Infect; 2015 Sep; 21(9):827-33. PubMed ID: 25980355 [TBL] [Abstract][Full Text] [Related]
9. Prophylactic HPV vaccination: past, present, and future. Castle PE; Maza M Epidemiol Infect; 2016 Feb; 144(3):449-68. PubMed ID: 26429676 [TBL] [Abstract][Full Text] [Related]
10. A prophylactic quadrivalent vaccine for the prevention of infection and disease related to HPV-6, -11, -16 and -18. Goldstone SE; Vuocolo S Expert Rev Vaccines; 2012 Apr; 11(4):395-406. PubMed ID: 22551023 [TBL] [Abstract][Full Text] [Related]
12. FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP). Centers for Disease Control and Prevention (CDC) MMWR Morb Mortal Wkly Rep; 2010 May; 59(20):630-2. PubMed ID: 20508594 [TBL] [Abstract][Full Text] [Related]
13. The human papillomavirus vaccines. Ljubojević S Acta Dermatovenerol Croat; 2006; 14(3):208. PubMed ID: 17010274 [TBL] [Abstract][Full Text] [Related]
14. A review of prophylactic human papillomavirus vaccines: recommendations and monitoring in the US. Dunne EF; Datta SD; E Markowitz L Cancer; 2008 Nov; 113(10 Suppl):2995-3003. PubMed ID: 18980283 [TBL] [Abstract][Full Text] [Related]
15. Post-licensure monitoring of HPV vaccine in the United States. Markowitz LE; Hariri S; Unger ER; Saraiya M; Datta SD; Dunne EF Vaccine; 2010 Jul; 28(30):4731-7. PubMed ID: 20188681 [TBL] [Abstract][Full Text] [Related]
16. Primary prevention of cervical cancer: prophylactic human papillomavirus vaccines. Mandic A J BUON; 2012; 17(3):422-7. PubMed ID: 23033276 [TBL] [Abstract][Full Text] [Related]
17. Overview of the clinical development and results of a quadrivalent HPV (types 6, 11, 16, 18) vaccine. Villa LL Int J Infect Dis; 2007 Nov; 11 Suppl 2():S17-25. PubMed ID: 18162241 [TBL] [Abstract][Full Text] [Related]
18. Vaccines against human papillomavirus infections: protection against cancer, genital warts or both? Joura EA; Pils S Clin Microbiol Infect; 2016 Dec; 22 Suppl 5():S125-S127. PubMed ID: 28034371 [TBL] [Abstract][Full Text] [Related]